GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MET097

Company
Pfizer
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for MET097 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06924320

    A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

    Not yet reported, Not yet reported Pfizer 381 participants Est. completion 2026-09-15 1 site Stand-alone
    Other conditions: Obesity and Obesity-related Medical Conditions
    View official trial listing →
  • Recruiting NCT NCT07519135

    A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function

    Not yet reported Pfizer 26 participants Est. completion 2027-07-09 3 sites
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT06712836

    A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight

    Not yet reported Pfizer 239 participants Est. completion 2026-04-30 2 sites Stand-alone
    Other conditions: Obesity, Overweight or Obesity
    View official trial listing →
  • Completed NCT NCT06857617

    This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

    Not yet reported, Not yet reported Metsera, a wholly owned subsidiary of Pfizer 120 participants Est. completion 2025-03-15 3 sites Stand-alone
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Completed NCT NCT06897202

    A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

    Not yet reported Pfizer 133 participants Est. completion 2026-03-18 29 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity in Diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT06973720

    A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight

    Not yet reported Pfizer 268 participants Est. completion 2026-10-16 5 sites Stand-alone
    Other conditions: Obesity, Overweight or Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07311850

    Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

    Not yet reported Pfizer 3578 participants Est. completion 2028-04-25 169 sites Stand-alone
    Other conditions: Obesity and Overweight
    View official trial listing →
  • Active, not recruiting NCT NCT07400653

    A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

    Not yet reported Pfizer 1078 participants Est. completion 2028-05-16 188 sites
    Type 2 diabetes Other conditions: Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
    View official trial listing →
  • Completed NCT NCT07400679

    A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity

    Not yet reported Pfizer 48 participants Est. completion 2026-07-08 1 site
    Other conditions: Overweight, Obesity, Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT07508241

    A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

    Not yet reported Pfizer 22 participants Est. completion 2027-01-27 1 site
    Other conditions: Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
    View official trial listing →
  • Not yet recruiting NCT NCT07794761

    A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

    Not yet reported Pfizer 180 participants Est. completion 2029-03-14 12 sites
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07794774

    A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

    Not yet reported Pfizer 197 participants Est. completion 2029-02-21 11 sites
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

The Weekly Dose & livestreams

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.